Allergan, Inc.

Allergan Sales, Inc.

Other

Syntaxin Limited

Health Protection Agency

The Secretary of State for Health

Ipsen Bioinnovation Limited

Secretary of State for Health and Social Care

Michael W. Grayston

Judith M. Leon

Steven R. Carlson

K. Roger Aoki

K Roger Aoki

Judith M Leon

Michael W Grayston

Steven R Carlson

Lance Steward

Ester Fernandez-Salas

Wei-Jen Lin

Athena Spanoyannis

Todd M Herrington

Joseph Francis

Keith Foster

John Andrew Chaddock

Philip Marks

Patrick Stancombe

Charles Penn

Stephen R Carlson

Use of a therapeutic molecule, for the treatment of specific pain conditions, wherein the therapeutic molecule is a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment can cleave a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that can bind to a Binding Site on the nociceptive sensory afferent, which Binding Site can undergo endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translation domain that can translocate the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent.

Treatment of pain

A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.

Botulinum toxin treatments

The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.

Post-translational modifications and clostridial neurotoxins

A method for treating a patient suffering from arthritis and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxic component of neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.

Use of the neurotoxic component of a botulinum toxin for treating arthritis

The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xDxxxLL (SEQ ID NO: 111) at the C-terminus, wherein x is any amino acid.

Chimera botulinum toxin type E

The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.

Nucleic acids encoding chimera botulinum toxin type E

The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived fromtoxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.

Post-translational modifications and Clostridial neurotoxins

Post-translation modification and clostridial neurotoxins

Methods for treating myofascial pain

The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridialtoxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.

Methods for treating arthritis pain

Method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of,toxin types A, B, C, D, E, F and G.

Method for treating secretions and glands using botulinum toxin

A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting oftoxin types A, B, C, D, E, F and G.

Use of botulinum toxins for treating various disorders and conditions and associated pain

Method for treating pain with botulinum toxin type B

Growing community of inventors

Coto de Caza, CA, United States of America

K Roger Aoki